DISCRIPTION
Laskinall is laser-based aesthetic equipment dedicated to highly effective and ideal for skin care. This convergence product is a low-output laser device for skin care that irradiates laser of two different wavelengths on the skin surface and subcutaneous fat tissue, and is designed conveniently for home use. Do skin care conveniently at home without experiencing the skin scraping caused by laser.
Laskinall
■ It is a medical device that maximizes the skin care effect or alleviation on the skin disease
by providing the synergy effect between the functional cosmetic for skin care (toner) and
low-output laser irradiation (Korean Patent Registration No. 10-1556962, September 2015).
■ It is consisting of the airbrush unit that sprays the functional cosmetic water made of
natural bio ingredient in the air mist form (20 μm), the ultrasonic massage modules that
physically promote absorption of toner into skin tissue (varies from product), and low-
output laser irradiator.
■ Functional toner made of specialized natural bio ingredients is comprised of
(1) skin care (2) skin disease improvement / alleviation lineup.
FEATURES
- Promoted absorption of toner using air brush spraying the functional toner and ultrasound
massage module.
- Recover and boost skin cell metabolism via low-output laser. Provide efficacy of treating
dermatitis disease.
- Integrating 3 functions into 1 function ensures convenience while maximizing skin care
effect or improvement in skin disease thanks to synergy effect.
- Minimize adverse effects thanks to the use of toner made of natural ingredients.
- Functional toner made of natural bio ingredients
▷ Function to improve treatment effect of skin diseases (atopy, eczema, acne, etc.)
▷ Function to inhibit skin ageing
▷ Skin moisturizing function
▷ Function to promote skin regeneration
▷ Function to improve skin cell metabolism
▷ Aroma therapeutic function
SPECIFICATION
Main body, Handy sprayer, Toner
OTHERS
Completed patent registration in 2015.
This product is medical equipment.
(Release scheduled for 4Q 2017)